股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: 興科蓉醫藥控股有限公司 (根據開曼群島法例註冊成立的有限公司) 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06833 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.0001 HKD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.0001 HKD | | 1,000 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 興科蓉醫藥控股有限公司 (根據開曼群島法例註冊成立的有限公司) 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 FF301 第 2 頁 共 10 頁 v 1.1.1 III.已發行股份及/或庫存股份變動詳情 (A). 股份期權（根據發行人的股份期權計劃） | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06833 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.0001 HKD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | HK ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 茲提述(i)興科蓉醫藥控股有限公司（「本公司」）所刊發日期為2025年5月30日 及 2025年8月15日內容有關（其 中 包 括）於2021年3月1日向黃祥彬先生提供5百萬港 元 免 息 貸 款 的 公 告；及(ii)日期為2025年10月20日內容有關內部控制顧問進行內 部控制檢討的主要審查結果的公告（統 稱「該等公告」）。除 本 公 告 另 有 界 定 外， 本 公 告 所 用 詞 彙 與 該 等 公 告 所 界 定 者 具 有 相 同 涵 義。 內部控制檢討的主要審查結果 於2025年10月20日，該 等 顧 問 向 董 事 會 及 委 員 會 提 交 內 部 控 制 報 告。該 內 部 控 制報告載有內部控制檢討的主要審查結果以及該等顧問為解決內部控制檢討 期 間 所 發 現 的 不 足 之 處 而 提 出 的 改 善 建 議。有 關 進 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 興科蓉醫藥控股有限公司 (根據開曼群島法例註冊成立的有限公司) 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06833 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | 0.0001 | HKD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | 0.0001 | HKD | | 1,0 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06833 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.0001 HKD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.0001 HKD | | 1,000,000 | 本月底法定/註冊股本總額： HKD 1,000,000 第 1 頁 共 10 頁 v 1.1.1 FF301 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Sinco Pharmaceuticals Holdings Limited 興科蓉醫藥控股有限公司 （根 據 開 曼 群 島 法 例 註 冊 成 立 的 有 限 公 司） （股 份 代 號：6833） 內部控制檢討的主要審查結果 茲提述興科蓉醫藥控股有限公司（「本公司」）日期為2025年5月30日 及2025年8月 15日內容有關（其 中 包 括）於2021年3月1日向黃祥彬先生提供5百萬港元免息貸 款的公告（統 稱「該等公告」）。除 本 公 告 另 有 界 定 外，本 公 告 所 用 詞 彙 與 該 等 公 告 所 界 定 者 具 有 相 同 涵 義。 內部控制檢討的主要審查結果 背 景 為 解 決 違 規 事 項 後 所 發 現 的 問 題，本 公 司 於2025年7月9日委聘該等顧問進行內 部 控 制 檢 討 並 向 董 事 會 提 出 適 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 興科蓉醫藥控股有限公司 (根據開曼群島法例註冊成立的有限公司) 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06833 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.0001 | HKD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.0 ...

Financial Performance - The Group's revenue decreased by 21.7% or RMB331.1 million to RMB1,195.8 million for the Reporting Period, compared to RMB1,526.9 million for the same period in 2024[12]. - Gross profit decreased by RMB42.5 million to RMB130.7 million, with a gross profit margin decline from 11.3% to 10.9% due to intensified market competition[12]. - Net profit slightly increased by RMB0.5 million to RMB24.4 million, attributed to a greater decrease in overall expenses compared to revenue and gross profit declines[12]. - Basic and diluted earnings per share amounted to RMB0.0120 for the Reporting Period, up from RMB0.0117 in the previous year[12]. - The decline in revenue from pharmaceutical products was approximately RMB329.5 million, while revenue from medical beauty services decreased by RMB1.6 million[12]. - Revenue from pharmaceutical products was RMB1,186.3 million, representing a decrease of approximately 21.7% or RMB329.5 million compared to the first half of 2024, primarily due to intensified market competition and softening demand[41]. - Revenue from medical beauty services amounted to RMB9.5 million, a decrease of approximately 14.4% or RMB1.6 million compared to the first half of 2024, attributed to economic slowdown and overall consumption downgrade[41]. - The Group recorded a gross profit of RMB130.7 million, a decrease of RMB42.5 million compared to RMB173.2 million in the corresponding period of 2024, with a gross profit margin declining from 11.3% to 10.9%[43][44]. - Cost of sales was RMB1,065.1 million, a decrease of RMB288.5 million or 21.3% compared to RMB1,353.6 million in the corresponding period of 2024, aligning with the decrease in sales revenue[42][49]. Assets and Liabilities - Total assets decreased to RMB1,879.8 million from RMB2,000.4 million, while total liabilities decreased to RMB1,196.2 million from RMB1,337.5 million[13]. - Total equity increased to RMB683.6 million from RMB662.9 million, indicating a strengthening of the company's financial position[13]. - Cash and cash equivalents decreased to RMB254.7 million from RMB411.4 million, reflecting liquidity challenges[13]. - The inventory balance decreased to RMB274.0 million as of June 30, 2025, down RMB78.3 million from the year-end balance of 2024, primarily due to a decrease in the inventory of human albumin[58]. - Trade receivables increased to RMB618.7 million as of June 30, 2025, up RMB109.0 million from the year-end balance of 2024, due to higher credit lines granted to distributors to stabilize sales[60]. - Trade and bills payables amounted to RMB919.6 million, an increase of RMB31.6 million compared to the year-end balance of 2024, primarily due to increased payables for the purchase of human albumin solution[69]. - Other payables and accruals decreased to RMB22.7 million, down RMB26.7 million from the year-end balance of 2024, mainly due to a reduction in contingent consideration payables[70]. Cash Flow and Investments - The Group's net cash used in operating activities was approximately RMB13.3 million, significantly improved from RMB268.0 million in the same period of 2024[80]. - The net cash outflow from investing activities for the reporting period was approximately RMB13.1 million, a decrease of RMB8.4 million compared to the same period in 2024, primarily due to a reduction in expenditures for property, plant, and equipment by RMB8.9 million[84]. - The net cash used in financing activities during the reporting period was approximately RMB58.0 million, down from RMB115.6 million in the same period of 2024, mainly due to a net repayment of bank borrowings of RMB119.3 million[85]. - The Group's capital expenditure for the six months ended June 30, 2025, was RMB6.7 million, significantly lower than RMB15.6 million for the same period in 2024[93]. Corporate Governance and Compliance - The Board resolved not to declare any interim dividend for the Reporting Period, consistent with the previous year[12]. - The Company has complied with all applicable code provisions under the Corporate Governance Code during the Reporting Period[130]. - The Group's operations are subject to relevant laws and regulations in the Cayman Islands, British Virgin Islands, Hong Kong, and the PRC, and it complied with all applicable laws during the Reporting Period[125]. - The Group's risk management strategy includes evaluating material risk exposure and implementing internal control measures to ensure effective operations[117]. - The Company is committed to maintaining high standards of corporate governance to enhance corporate value and accountability[130]. Strategic Focus and Future Plans - The Group focuses on blood products and provides comprehensive MPCM services for small and medium-sized overseas pharmaceutical manufacturers[14]. - The Group is focusing on high-quality product portfolios and channel penetration strategies to improve regional coverage and terminal penetration efficiency amid increasing industry competition and narrowing gross profit margins[27][29]. - The Group aims to enhance its supply chain layout and market-response mechanisms while promoting clinical-oriented product structure upgrades[32]. - The Group will increase R&D investment in new medical materials and medical beauty consumables to advance product diversification[33]. - The Group plans to launch new medical beauty products in the third quarter of 2026, following the completion of clinical trials in the fourth quarter of 2025[33]. Employee and Operational Insights - As of June 30, 2025, the Group had a total of 268 employees, with total staff costs amounting to RMB27.6 million, an increase from RMB24.2 million for the same period in 2024[110]. - The Group provides continuous learning and training programs to enhance employee skills and maintain competitiveness[112]. - The Group's employee performance appraisals are conducted annually, influencing salary reviews and bonus considerations[111]. - The Group's employee remuneration policy is influenced by local market conditions, industry standards, inflation, corporate efficiency, and employee performance[111]. Shareholder Information - As of June 30, 2025, Mr. Huang holds 1,050,000,000 shares, representing approximately 51.65% of the total shareholding[151]. - The total number of shares in issue as at June 30, 2025 is 2,032,890,585[155]. - The 2025 Share Option Scheme allows for the issuance of up to 203,289,058 shares, which is 10% of the issued share capital[175]. - The maximum entitlement for any participant under the 2025 Share Option Scheme is limited to 1% of the issued share capital in any 12-month period[176]. - The 2025 Share Option Scheme is valid for approximately 9 years and 11 months from May 26, 2025[174]. - A total of 30,000,000 options were granted under the previous 2016 Share Option Scheme, with 12,000,000 options exercised and none outstanding as of the latest practicable date[164]. - The 2016 Share Option Scheme was terminated on May 26, 2025, to adopt the new 2025 Share Option Scheme[165]. Loan and Financial Transactions - The Company provided an interest-free loan of HK$5,000,000 to Mr. Huang, which was fully repaid on June 25, 2021[188]. - The loan transaction was subject to reporting and independent shareholders' approval requirements under Chapter 14A of the Listing Rules, as the applicable percentage ratios were above 0.1% but less than 5%[194]. - The Company acknowledged that providing the loan breached its Articles and applicable Listing Rules, necessitating shareholder approval for the resolutions at an extraordinary general meeting[195].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 興科蓉醫藥控股有限公司 (根據開曼群島法例註冊成立的有限公司) 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06833 | | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 2,032,890,585 | | 0 | | 2,032,890,585 | | 增加 / 減少 (-) | | | | | | | | | | 本月底結存 | | | | 2,032,890,585 | | 0 | ...

Core Viewpoint - Xinkelong Pharmaceutical (06833) reported a net profit attributable to shareholders of 24.39 million yuan, reflecting a year-on-year increase of 2.17% despite a revenue decline of 21.68% to 1.196 billion yuan for the six months ending June 30, 2025 [1] Financial Performance - The company achieved revenue of 1.196 billion yuan, which represents a decrease of 21.68% compared to the previous year [1] - The net profit attributable to shareholders was 24.39 million yuan, showing a year-on-year increase of 2.17% [1] - Basic earnings per share were reported at 0.012 yuan [1]